Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 07/10/2026 | CALL | $254.00 | 2,600 | +2,600 | |
| 07/10/2026 | PUT | $254.00 | 2,600 | +2,600 | |
| 11/20/2026 | CALL | $290.00 | 1,637 | +1,115 | +213.60% |
| 08/21/2026 | CALL | $260.00 | 3,048 | +1,100 | +56.47% |
| 09/18/2026 | CALL | $250.00 | 3,307 | +528 | +19.00% |
| 06/17/2027 | PUT | $250.00 | 553 | +514 | +1,317.95% |
| 07/02/2026 | CALL | $230.00 | 269 | -27 | -9.12% |
| 08/21/2026 | CALL | $230.00 | 2,107 | -29 | -1.36% |
| 09/18/2026 | PUT | $165.00 | 728 | -38 | -4.96% |
| 09/18/2026 | CALL | $270.00 | 2,158 | -43 | -1.95% |
| 07/02/2026 | CALL | $235.00 | 256 | -73 | -22.19% |
| 07/17/2026 | CALL | $250.00 | 1,797 | -142 | -7.32% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.94% | 52.04M | 7.5B |
| Vanguard 500 Index Fund | 2.21% | 39.11M | 5.63B |
| SPDR S&P 500 ETF Trust | 1.07% | 18.95M | 2.73B |
| Fidelity 500 Index Fund | 1.06% | 18.76M | 2.7B |
| iShares Core S&P 500 ETF | 0.89% | 15.65M | 2.25B |
| Vanguard Index-Value Index Fund | 0.86% | 15.28M | 2.2B |
| American Mutual Fund Inc | 0.85% | 14.95M | 2.15B |
| Select Sector SPDR Fund-Health Care | 0.80% | 14.17M | 2.04B |
| Capital Income Builder, Inc. | 0.74% | 13.1M | 1.89B |
| Vanguard Institutional Index Fund-Institutional Index Fund | 0.74% | 13.09M | 1.89B |
| Washington Mutual Investors Fund | 0.65% | 11.5M | 1.66B |
| JP Morgan Large Cap Growth Fund | 0.42% | 7.5M | 1.08B |
| American Balanced Fund | 0.42% | 7.49M | 1.08B |
| Price (T.Rowe) Value Fund | 0.40% | 7.06M | 1.02B |
| College Retirement Equities Fund-Stock Account | 0.33% | 5.77M | 830.72M |
| Columbia Fds Ser Tr I-Columbia Dividend Income Fd | 0.31% | 5.4M | 778.54M |
| Price (T.Rowe) U.S. Value Equity Trust | 0.31% | 5.4M | 777.91M |
Big Pharma Has a Case of Merger Mania
06/30 12:26 am
The Motley Fool
Read moreAbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
06/29 11:21 am
The Motley Fool
Read moreNew study examines real-world switching patterns after patients transition from Humira to biosimilars
06/29 09:00 am
GlobeNewswire Inc.
Read moreHere's How Much You'd Need to Invest in HDV to Generate $500 per Month in Dividends
06/23 02:02 pm
The Motley Fool
Read more3 Monster Stocks to Hold for the Next 10 Years
06/23 06:05 am
The Motley Fool
Read moreAbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?
06/22 06:36 pm
The Motley Fool
Read moreShould You Buy Moderna Before Aug. 5?
06/22 06:10 pm
The Motley Fool
Read more5 Dividend Stocks to Buy and Hold Forever
06/22 06:15 am
The Motley Fool
Read moreGlobal Hyperpigmentation Treatment Market Size to Surpass USD 2.85 Billion by 2035, Growing at a 6.5% CAGR – SNS Insider
06/21 10:25 pm
GlobeNewswire Inc.
Read moreAbbVie Declares Quarterly Dividend
06/18 04:05 pm
Benzinga
Read moreGenmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
06/13 12:45 pm
GlobeNewswire Inc.
Read moreTeva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
06/12 04:05 pm
The Motley Fool
Read moreAbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients
06/12 10:30 am
Benzinga
Read moreAbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.
06/12 06:15 am
The Motley Fool
Read moreKyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
06/08 02:34 pm
The Motley Fool
Read moreADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data Supporting the Ongoing Phase 3 STOP-HAE Clinical Trial at the 2026 Annual EAACI Congress
06/08 09:00 am
GlobeNewswire Inc.
Read moreState Street's Health Care ETF Tops Invesco's on Yield and Returns
06/02 07:10 am
The Motley Fool
Read moreAbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
06/01 02:19 pm
The Motley Fool
Read moreVHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost
05/28 08:07 am
The Motley Fool
Read moreGLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.
05/27 11:17 am
The Motley Fool
Read morePrediction: These 2 Obesity Drug Stocks Could Double in 2026
05/26 04:04 am
The Motley Fool
Read moreThe Smartest Growth Stocks to Invest $10,000 in As Investors Rotate Out of Tech
05/22 09:15 pm
The Motley Fool
Read moreIchnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors
05/20 07:00 am
GlobeNewswire Inc.
Read morePulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
05/19 01:00 pm
GlobeNewswire Inc.
Read more2 Stocks That Are Much Cheaper Than They Look
05/19 09:30 am
The Motley Fool
Read more2 High-Yield Healthcare Stocks to Buy Before They Raise Payouts
05/19 06:30 am
The Motley Fool
Read moreA Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?
05/11 05:15 pm
The Motley Fool
Read morePresbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight
05/11 01:00 pm
GlobeNewswire Inc.
Read moreWhat to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress
05/10 01:37 pm
The Motley Fool
Read moreWant Reliable Dividend Income in May? These 2 Stocks Deliver
05/06 04:10 am
The Motley Fool
Read moreWant to Collect a High Dividend Every Month? Invest in These 3 Stocks
05/05 12:30 pm
The Motley Fool
Read moreAbbVie's Latest Results Reveal a Trend Investors Shouldn't Overlook
05/04 04:30 pm
The Motley Fool
Read more3 of the Best Dividend Stocks to Buy in May 2026
05/04 04:26 pm
The Motley Fool
Read moreNxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026
05/01 02:36 am
GlobeNewswire Inc.
Read moreAbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
04/30 03:00 pm
GlobeNewswire Inc.
Read moreAbbVie et adMare BioInnovations nomment RIME Therapeutics lauréat du Prix AbbVie des innovateurs en biotechnologies au Québec
04/30 03:00 pm
GlobeNewswire Inc.
Read moreAbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience Strength
04/29 02:49 pm
Benzinga
Read moreRheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
04/28 01:00 pm
GlobeNewswire Inc.
Read moreAbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug
04/24 08:46 am
Benzinga
Read moreMental Health Clinical Trials Research Report 2026: $4.89 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
04/24 04:57 am
GlobeNewswire Inc.
Read moreBispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook
04/21 04:34 am
GlobeNewswire Inc.
Read moreNxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
04/20 02:30 am
GlobeNewswire Inc.
Read moreThe Psychedelic Revolution in Mental Healthcare
04/17 04:19 pm
The Motley Fool
Read moreNon-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight
04/16 01:00 pm
GlobeNewswire Inc.
Read more3 High-Yielding Dividend Stocks to Buy, Even If You're Worried About the Market
04/15 11:15 am
The Motley Fool
Read moreEli Lilly's Jaypirca Builds Case With Fourth Positive Phase 3 Trial In Blood Cancer Patients
04/13 09:29 am
Benzinga
Read moreS&P 500 Index Dividend Yields Are Teasing All-Time Lows. Here Are 3 Dividend Darlings That Crush This Trend.
04/13 06:24 am
The Motley Fool
Read more3 Companies Aggressively Raising Dividends While Others Play Defense
04/10 03:17 pm
Investing.com
Read more